What Analysts Are Predicting for BMY—Don't Miss Out!

Introduction

Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company known for blockbuster drugs in oncology, cardiovascular, and immunology. Despite its strong portfolio, BMY’s stock performance has lagged the market recently – the shares were down about 20% in 2023 even as the S&P 500 rose (www.trefis.com). This decline reflects investor concerns over upcoming patent expirations and pipeline setbacks. Analysts currently hold a lukewarm view: out of ~20 analysts covering BMY, 8 rate it a Buy and 11 rate it Hold, yielding a consensus Hold recommendation (www.marketbeat.com). The average 12-month price target is around $59, roughly in line with the recent share price (www.marketbeat.com), suggesting limited near-term upside according to Wall Street. Nonetheless, some observers see a potential bargain given BMY’s defensive business and generous dividend – don’t overlook the factors analysts are weighing.

Dividend Policy & Yield

BMY has a long history of paying – and steadily increasing – dividends. The company recently declared a quarterly dividend of $0.63 per share, a 1.6% increase from the prior rate (news.bms.com). At the new rate (annualized $2.52 per share), the dividend yield is about 4.2% as of early 2026 (www.macrotrends.net). This yield is well above the broader market average and is higher than many pharma peers. Importantly, 2026 will mark BMY’s 17th consecutive year of dividend hikes, and the company has paid dividends for 94 years straight (news.bms.com) – underlining management’s commitment to returning cash to shareholders.

BMY’s dividend payout has grown modestly each year; for example, cash dividends per share were $2.31 in 2023, $2.42 in 2024, and $2.49 in 2025 (www.sec.gov). Even with recent earnings pressures, these dividends appear sustainable. In 2025, BMY paid out about $5.0 billion in dividends (www.sec.gov), which was comfortably covered by the year’s operating cash flow of $14.2 billion (www.sec.gov). In other words, dividends consumed roughly 35% of BMY’s operating cash generation, leaving plenty of cushion for debt reduction and reinvestment. The payout ratio against non-GAAP earnings was around 40%, though it was higher against GAAP net income due to one-time charges (www.sec.gov). Overall, the dividend is well-covered and has room for continued (if modest) growth, barring a severe downturn. Shareholders also benefited from buybacks – BMY repurchased about $5.3 billion of its stock in 2025 (www.sec.gov) – although future repurchases may depend on cash needs for new drug development. The key takeaway is that BMY offers an attractive income stream, and management has prioritized maintaining that dividend streak.

Leverage, Debt Maturities & Coverage

BMY carries a significant debt load stemming largely from its acquisitions (notably Celgene in 2019 and more recent deals). As of late 2025 the company had about $51 billion in total debt outstanding (www.trefis.com), partially offset by cash holdings (~$12 billion) for a net debt of roughly $34 billion (www.sec.gov). This capital structure is manageable for a company of BMY’s size, but it does constrain financial flexibility. Indeed, credit rating agencies have taken note: after a string of deals (including the Mirati, Karuna, and RayzeBio acquisitions in 2023–24), Standard & Poor’s downgraded BMY’s long-term credit rating from A+ to A with a stable outlook (www.sec.gov). The downgrade reflects higher leverage and interest burden, though BMY remains solidly investment-grade.

Reassuringly, BMY has been using its ample cash flow to deleverage. In 2025 alone, the company reduced its net debt position by about $4.4 billion (www.sec.gov). It also retired $1.9 billion of maturing notes that year, after paying down $2.9 billion in 2024 (www.sec.gov). The debt maturity schedule looks very manageable: over the next five years (2026–2030) BMY faces bond maturities of roughly $2.0 billion per year (with a lighter $544 million in 2028) (www.sec.gov). Interest obligations on these debts run about $1.6–$1.8 billion annually through 2030 (www.sec.gov) – a figure well covered by earnings and cash flow. For context, BMY’s interest payments were $2.1 billion in 2025 (www.sec.gov), while that year’s EBITDA (as approximated by non-GAAP operating earnings) was over $12 billion, indicating a healthy interest coverage ratio on the order of 6× or more. Even on a cash basis, 2025 operating cash flow was nearly 7× the interest expense, underscoring that debt service is not an immediate threat.

Looking forward, BMY has ample liquidity – including cash, investments, and a $5 billion revolving credit facility extended to 2031 (www.sec.gov) – to meet its obligations. The company has stated it expects to pay down ~$10 billion of debt by 2026 (www.sec.gov), which would further ease leverage ratios. One caveat: rising interest rates have increased the cost of new debt and variable-rate borrowings, contributing to an uptick in interest expense from about $1.2 billion in 2023 to $2.1 billion in 2025 (www.sec.gov). If BMY needed to refinance large amounts of debt, higher rates could pinch. Fortunately, with staggered maturities and strong cash generation, BMY’s balance sheet appears resilient. The company’s A/A2 credit ratings and consistent access to capital markets support its financial stability – but investors should monitor future acquisition activity that might add leverage.

Valuation and Comparables

By multiple measures, BMY’s stock looks cheaply valued relative to both its pharma peers and the broader market. The company trades at roughly 1.9× trailing sales and about 7× free cash flow, compared to ~3.3× sales and 21× FCF for the S&P 500 (www.trefis.com). BMY’s price-to-earnings ratio is in the mid-teens on a TTM basis – around 17× recent earnings, versus ~24× for the S&P 500 (www.trefis.com). On a forward basis the discount is even steeper: based on 2025–26 consensus EPS around $6, the forward P/E is only ~9–10×, well below the pharma industry average. Such low multiples reflect investors’ cautious outlook on BMY’s growth (more on the headwinds below), but also suggest substantial upside if the company can execute through its challenges.

It’s worth noting that many large pharmaceutical stocks tend to trade at discounts to the market due to patent-cycle risk, but BMY’s valuation is at the low end even among big pharma. For instance, Merck and Pfizer currently trade near 13–14× forward earnings (with dividend yields ~3% and ~4.5%, respectively), whereas BMY is near 9× forward earnings with a ~4%+ yield (www.macrotrends.net) (www.macrotrends.net). BMY’s dividend yield of ~4.2% is also significantly higher than the S&P 500’s ~1.5–2% yield, indicating the market is assigning a higher risk premium to these shares. In fact, BMY’s free-cash-flow yield (the inverse of P/FCF) approaches 14%, an unusually high figure for a stable, cash-generative business (www.trefis.com). Some analysts argue this represents a value opportunity. For example, the Trefis research team in Sep 2025 concluded “the stock is attractive at ~$45” (when BMY was near its lows) based on the company’s moderate growth and robust cash flows, assigning a fair value of around $65 (www.trefis.com). While the stock has since rebounded into the mid-$50s, BMY still appears undervalued if it can navigate its transition period.

Of course, low valuation can be a double-edged sword – it may simply signal skepticism about future earnings. The consensus analyst forecast calls for a slight decline in EPS in 2026 (to around $6.00 from $6.54 in 2025) (uk.finance.yahoo.com), and revenue is expected to dip as legacy drugs face generic competition. Until investors see a clear path to renewed growth, BMY’s multiple may stay depressed. That said, the downside appears somewhat buffered at these levels: the stock’s dividend and buybacks provide support, and any positive surprise in drug development or sales could spur a re-rating. In summary, BMY’s valuation suggests a cautious but potentially rewarding setup – it’s priced for difficulty, but if the company outperforms low expectations, shareholders “won’t miss out” on significant upside.

Risks, Red Flags, and Open Questions

Investors must weigh several key risks in the BMY story. Front and center is the looming patent cliff. A number of BMY’s largest revenue drugs are facing or have recently faced loss of exclusivity (LOE), which can lead to rapid sales erosion. The poster child is Revlimid (lenalidomide), a multiple myeloma therapy acquired via Celgene. In the U.S., BMY had to allow limited generic entry for Revlimid starting in 2022 as part of patent settlement deals; those volume-limited generics caused Revlimid’s U.S. sales to plummet 49% in 2025 (www.sec.gov) (www.sec.gov). As of January 31, 2026, the generic restrictions have fully lifted, meaning Revlimid now faces full competition and its remaining ~$3 billion in annual revenue will dwindle quickly (www.sec.gov). The story is similar for Pomalyst (pomalidomide, another Celgene myeloma drug) – its patent rights were fully amortized by late 2025 (www.sec.gov), indicating generics are imminent. In Europe and Japan, both Revlimid and Pomalyst already have generic rivals (www.sec.gov) (www.sec.gov). BMY’s older oncology drugs like Sprycel (leukemia) and Yervoy (immunotherapy) are also past peak: Yervoy’s key patents expire in 2026 (www.sec.gov), and Sprycel generics have launched in some markets.

Another major cliff is coming with Eliquis (apixaban), BMY’s top-selling blood thinner (co-marketed with Pfizer). In the EU, Eliquis loses protection in late 2026 – in fact, generic competitors have already launched in certain European countries following legal challenges (www.sec.gov). In the U.S., BMY and Pfizer settled with generic makers to allow an Eliquis generic launch in 2028 (www.sec.gov). This drug alone contributed over $11 billion in annual revenue, so its gradual decline (Europe in 2026, U.S. by 2028) is a huge headwind. Compounding this, U.S. price regulation will hit Eliquis even before generics arrive: under the Inflation Reduction Act (IRA), Medicare has identified Eliquis as one of the first drugs for price “negotiation.” The Department of Health and Human Services announced a “maximum fair price” for Eliquis (30-day supply) effective Jan 1, 2026 in Medicare Part D (www.sec.gov) (www.sec.gov). Similarly, BMY’s Pomalyst was selected for Medicare price setting starting 2026 (www.sec.gov) (www.sec.gov). The IRA will materially lower reimbursement on these drugs for Medicare patients, pressuring BMY’s U.S. sales even before generics fully arrive. More of BMY’s portfolio could be subject to inflation rebates and future price controls under the IRA (www.sec.gov) (www.sec.gov).

These patent and pricing challenges mean BMY’s revenue is expected to trough over 2025–2026, which is reflected in analysts’ tempered forecasts. The critical open question is whether BMY’s newer products and pipeline can ramp up to fill the gap. The company has launched several promising drugs in recent years: e.g. Opdualag (a new combination immunotherapy for melanoma), Reblozyl (for anemia in certain disorders), Sotyktu (a pill for psoriasis), Camzyos (for a rare heart condition), and Breyanzi/Abecma (CAR-T cell therapies for blood cancers). Each of these targets significant markets, but it’s too early to tell if any will be “blockbuster” enough to offset the LOEs. Initial uptake for some has been modest. For instance, Sotyktu (deucravacitinib) launched into a competitive psoriasis market dominated by injectables, and Camzyos (mavacamten) – while a first-in-class agent for hypertrophic cardiomyopathy – saw a setback when a follow-up trial produced disappointing results (www.trefis.com). BMY’s much-anticipated new schizophrenia treatment Cobenfy (xanomeline/trospium, from its Karuna partnership) also showed mixed outcomes in long-term studies, with high patient dropout rates tempering enthusiasm (www.trefis.com) (apnews.com). These examples highlight pipeline risk: not every experimental indication will pan out as hoped, and some recently approved drugs might underwhelm in real-world use.

BMY’s strategy to bridge its growth gap has included bolt-on acquisitions (e.g. the $4.8 billion Mirati deal in 2023 for a oncology drug Krazati (www.sec.gov), and investments in biotech collaborations like the sizable alliance with BioNTech in oncology (www.sec.gov)). While these moves could yield long-term rewards, they also carry risks of their own – high upfront costs, integration challenges, and the possibility that the acquired assets don’t deliver the expected results. Shareholders have reason to be wary: the Celgene acquisition, though it brought valuable drugs, saddled BMY with debt and a controversial contingent value rights (CVR) situation that ended in litigation. More acquisitions could further stretch the balance sheet or distract from internal R&D. It’s a fine line for management to walk: they must innovate and replenish the pipeline, but also maintain financial discipline to protect the dividend and credit rating.

Other risks include the general regulatory and competitive environment. Drug pricing pressure isn’t limited to the IRA – globally, healthcare systems are pushing back on costs. Competition is fierce in every therapeutic area BMY plays in; for example, Merck’s Keytruda continues to dominate immuno-oncology, and upcoming generic or biosimilar rivals will target BMY’s top biologics (e.g. Opdivo’s U.S. exclusivity ends in 2028 (www.sec.gov)). Any delay or failure in clinical trials could derail an important future revenue stream. Finally, macroeconomic factors like rising interest rates (which increase borrowing costs) and foreign exchange swings can impact results, though these are secondary compared to the pharma-specific issues.

Bottom Line: BMY faces a challenging near-term outlook with shrinking sales from legacy products – a fact not lost on analysts or the stock’s cheap valuation. The company’s fate over the next few years will depend on its ability to execute new product launches and possibly deliver surprise breakthroughs. Investors will be watching closely to see if 2026 marks the bottom for BMY’s earnings and revenue, as the company navigates the loss of its older cash cows. On the positive side, BMY’s strong cash flows and prudent capital management have so far allowed it to reward shareholders with ongoing dividends and buybacks even during this transition. The open questions are: Can Bristol-Myers Squibb’s new drugs grow fast enough to rejuvenate the top line? Will management pursue further M&A to bolster the pipeline, and at what cost? And crucially for shareholders, can BMY maintain its dividend growth streak through the lean period? The answers to these will shape whether analysts remain on the sidelines or turn more bullish. Given the stock’s low expectations, any tangible progress – a hit product, an accretive deal, or simply better-than-feared financial results – could flip the narrative. Analysts may be wary now, but the coming 1–2 years are critical for BMY’s reset, and investors won’t want to miss how this unfolds.

Sources: Bristol-Myers Squibb 2025 Annual Report (Form 10-K) (www.sec.gov) (www.sec.gov); BMS Investor Press Releases (news.bms.com); Trefis Research (www.trefis.com) (www.trefis.com); MarketBeat Analyst Survey (www.marketbeat.com) (www.marketbeat.com); AP News (apnews.com); BMS 2025 Earnings Disclosures (www.sec.gov) (www.sec.gov).